NL-OMON54745招募中不适用
instantaneous wave-free ratio guided multi-vessel revascularization during percutaneous coronary intervention for acute myocardial infarction - iMODER
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 550
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Age 18 years and older
- •- Clinical presentation of STEMI and successful primary PCI within 12 hours
- •from onset of symptoms
- •- One or more other, noninfarct coronary artery lesions of >50% stenosis and
- •feasible to
- •be revascularized (i.e. minimal diameter 2mm)
排除标准
- •- History of ST-elevation myocardial infarction or coronary artery bypass graft
- •- Hemodynamic instability, respiratory failure, Kilips class >=III
- •- Refusal or inability to provide informed consent
- •- Life expectancy due to noncardiovascular co-morbidity of less than 12 months
- •- Chronic total occlusion
- •- Left main stem stenosis (>50%)
- •- Pregnancy
研究者
相似试验
招募中
不适用
instantaneous wave-Free Ratio based decision making in patients with ischemic heart disease undergoing directional coronary atherectomy followed by a paclitaxel-coated balloon angioplastyischemic heart diseaseJPRN-UMIN000032520Tsukazaki Hospital40
招募中
不适用
Relationship between instantaneous wave-free ratio and global longitudinal strain in patients with chronic coronary artery syndromechronic coronary artery diseaseJPRN-UMIN000044692Kita-harima Medical Center75
招募中
不适用
INTEGRAL studyDiffuse/tandem Coronary LesionsJPRN-jRCTs072200027Matsuo Hitoshi300
招募中
1 期
A Single-Arm, Open-Label, Multi-Centre, Phase Ib Study Evaluating the Safety and Preliminary Efficacy of AUTO1 in Pediatric Patients with CD19-Positive Relapsed/ Refractory (r/r) B cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B cell Non-Hodgkin Lymphoma (B NHL)B-cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL).MedDRA version: 21.0Level: LLTClassification code: 10000844Term: Acute lymphoblastic leukaemia Class: 10029104CTIS2023-506307-26-00Autolus Limited24
已完成
不适用
A study to evaluate the Safety and Efficacy of Nivolumab in Combination with Paclitaxel in Epstein-Barr Virus(EBV)-Related, or Microsatellite Instability-High (MSI-H), or Programmed Cell Death Ligand 1 (PD-L1) Positive Advanced Gastric CancerKCT0004186Yonsei University Health System, Severance Hospital62